mirumpharma.comHome - Mirum Pharma

Skip to footerOverview Leadership Compliance Our Science Therapeutic Areas Cholestasis Inborn Errors of Bile Acid Metabolism Cholesterol Metabolism Pipeline Publications & Presentations Medical Affairs Patients & Families Patient Stories Resources Our Medicines LIVMARLI LIVMARLI Availability LIVMARLI in the U.S. LIVMARLI in the E.U. Mirum Access Plus (MAP) Cholbam Chenodal Life at Mirum The Mirum Experience Join Our Circle Investors Overview News & Events Financials Stock Stock Quote & Chart Historical Price Lookup Analyst Coverage Corporate Governance Resources Contact Us THE SCIENCE. THE PEOPLE. THE POTENTIAL. NOTHING SHORT OF REMARKABLE A remarkable unmet need In Latin, mirum” means remarkable. In science, we develop remarkable therapies for a deserving community. When we discovered that there was an unmet need for people living with rare liver disease, we got to work. It was imperative to us to identify and develop treatments that had the potential to transform the lives of patients and their families. That’s why our name is so fitting. See What Guides Us Developing medicines with the potential to change lives Where others see unmet need solely as a treatment gap, we envision a unique opportunity to revitalize a community like never before. Our need to develop transformative medicine is propelled by our passion for patients and their loved ones, and we’re focused on turning possibilities into realities. Learn about our science Transformative scientific discoveries Driven by data and meaningful evidence, we are dedicated to transforming scientific discoveries into therapies poised to change the trajectory of rare liver diseases for generations to come. Explore what’s in development Meet some remarkable people Patients and families living with rare liver diseases are at the center of everything we do. We invite you to meet some of the people in this community and learn more about living with rare liver disease. Watch Stories Mirum’s headlines Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference Footer Contact Us Terms of Use Privacy Policy CA...